



Resource impact template

Resource impact

Published: 19 November 2025

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for hormone-sensitive metastatic prostate cancer:

- [Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer](#) (2025) NICE technology appraisal guidance 1109
- [Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer](#) (2023) NICE technology appraisal guidance 903
- [Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer](#) (2021) NICE technology appraisal guidance 741
- [Enzalutamide for treating hormone-sensitive metastatic prostate cancer](#) (2021) NICE technology appraisal guidance 712